Treatment plan for children with acute lymphoblastic leukemia, observed
Observes new treatment guidelines in children under 18 with acute lymphoblastic leukemia.
Plain-language title generated from the registry record
Registry title: Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOP
Key facts
- Where
- Dakar, SenegalSee the site
Where in Senegal
- Hôpital Aristide Le Dantec, Avenue Pasteur,Dakar, SenegalTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- French Africa Pediatric Oncology Group
- Trial code
- NCT04794296
- Record updated
- 2 March 2026
- Original description
The LALGFA2019 Recommendations redefine the standard risk criteria and propose to introduce anthracycline induction in so-called high-risk forms (LAL line T and LAL line B with leukocytosis greater than or equal to 50 G/L or in children less than 1 year of age or more than 10 years of age) as well as Endoxan and Methotrexate in high dose consolidation.Read full original descriptionShow less
Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOP
The LALGFA2019 Recommendations redefine the standard risk criteria and propose to introduce anthracycline induction in so-called high-risk forms (LAL line T and LAL line B with leukocytosis greater than or equal to 50 G/L or in children less than 1 year of age or more than 10 years of age) as well as Endoxan and Methotrexate in high dose consolidation.
Inclusion: Children 0 to 18 ALL first diagnosis No prior chemotherapy Cytology FAB L1 or L2; -.
Exclusion: ALL L3 (Burkitt) ALL previously treated with chemotherapy Trisomy 21.